Study Links Menopausal Hormone Therapy to 69% Lower Low-Bone-Density Risk

3 articles · Updated · Medical News Today · Jun 15

387 postmenopausal women were analyzed in a retrospective cohort, and MHT users showed a 69% lower adjusted odds of low bone mineral density than non-users.
31.8% of women on MHT had low bone mineral density versus 56.2% of non-users, with significantly higher lumbar-spine and hip bone-density scores in the treatment group.
Researchers said the findings add real-world evidence that MHT may help preserve bone health and reduce fracture risk, though they lacked details on specific hormone regimens or delivery methods.
Experts said the result aligns with long-standing evidence on bone protection, but stressed MHT is not suitable for everyone because risks can include uterine cancer, stroke, heart attack and breast cancer.
ENDO 2026 presented the study before peer-reviewed publication, and the lead author said the observational design shows association rather than causation.

Sources

Medical News Today12h ago

Study: Menopausal Hormone Therapy Linked to 69% Lower Risk of Low Bone Mineral Density

AOL12h ago

Menopause hormone therapy slashes risk of low bone density, new data shows - AOL

health.yahoo.com12h ago

Worried About Menopausal Bone Loss? Study Shows This Provides Protection For Women

4 Sources

With FDA warnings on hormone therapy gone, is it the best defense against fractures?

Could your heart health predict your risk of a debilitating hip fracture after menopause?

Why might a common diabetes drug be silently destroying the bones of postmenopausal women?

Menopausal Hormone Therapy and Bone Health: New Evidence, Regulatory Changes, and the Future of Osteoporosis Prevention

Overview

Menopausal hormone therapy (MHT) is entering a new era, as recent clinical findings and a renewed focus on personalized patient care are changing how it is viewed. Once seen mainly as a way to relieve menopausal symptoms, MHT is now recognized for its important benefits in protecting bone health. This shift is driven by strong evidence showing that MHT can independently safeguard bones, offering a dual purpose: symptom relief and prevention of bone loss. As a result, MHT is becoming a key part of strategies to maintain skeletal integrity during and after menopause.

...